4CPS-242 Isavuconazole treatment in two paediatric patients during extracorporeal membrane oxygenation support: the role of therapeutic drug monitoring

Autor: A Pau Parra, M Pujol Jover, S Melendo Pérez, A Fernández-Polo, M Miarons, J Izquierdo Blasco, S García-García, BFernández Ledesma, MJ Cabañas-Poy, J Balcells, S Clemente-Baustista

Publikováno v: Section 4: Clinical pharmacy services.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::413a4b86a6270764ac5215bfba09fd21
https://doi.org/10.1136/ejhpharm-2023-eahp.217

4CPS-197 Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs

Autor: P Marrero Álvarez, A Fernández Polo, C Cañete Ramírez, P Sanchez-Sancho, BM García Palop, M Garau Gomila, MJ Cabañas Poy, MQ Gorgas Torner

Publikováno v: Section 4: Clinical pharmacy services.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a7aeee5d5de26ffed6ae58c5224e38c
https://doi.org/10.1136/ejhpharm-2022-eahp.198

4CPS-126 A population pharmacokinetic model of adalimumab in a cohort of paediatric patients with inflammatory bowel disease: a preliminary analysis

Autor: S. Clemente Bautista, M Miarons Font, MJ Cabañas Poy, N Rebollo Diaz, JS Pérez Blanco, O Segarra Cantón, MQ Gorgas, JG Sánchez Hernandez, MJ Otero, R Torres Peral

Publikováno v: Section 4: Clinical Pharmacy Services.

Background and importance Therapeutic drug monitoring is useful to optimise adalimumab therapy in patients with inflammatory bowel disease (IBD). Aim and objectives The objective of this study was to perform a preliminary pharmacokinetic (PK) model o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6feb938cb4c8d275450ce69d1f3a9e23
https://doi.org/10.1136/ejhpharm-2020-eahpconf.227

3D printed personalized therapies for pediatric patients affected by adrenal insufficiency.

Autor: Rodríguez-Pombo L; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Gallego-Fernández C; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Jørgensen AK; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK., Parramon-Teixidó CJ; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cañete-Ramirez C; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cabañas-Poy MJ; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Basit AW; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK.; FABRX Ltd., Henwood House, Henwood, Ashford, Kent, UK.; FABRX Artificial Intelligence, Carretera de Escairón, 14, Currelos (O Saviñao), Spain., Alvarez-Lorenzo C; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Goyanes A; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK.; FABRX Ltd., Henwood House, Henwood, Ashford, Kent, UK.; FABRX Artificial Intelligence, Carretera de Escairón, 14, Currelos (O Saviñao), Spain.

Publikováno v: Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Nov; Vol. 21 (11), pp. 1665-1681. Date of Electronic Publication: 2024 Sep 18.

Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit.

Autor: Clemente Bautista S; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain., Jiménez Lozano I; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain., Castellote Belles L; Clinical Biochemistry Department, Vall d'Hebron University Hospital, Barcelona, Spain., Parramón-Teixidó CJ; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain., Garcia Esquerda C; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain., Puertas Sanjuan A; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain., Daina Noves C; Pediatric Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain., Segura Encinas V; Pediatric Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain., Cabañas Poy MJ; Pharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Publikováno v: Hospital pharmacy [Hosp Pharm] 2024 Oct; Vol. 59 (5), pp. 557-561. Date of Electronic Publication: 2024 Apr 15.